Alcon announces Academy research. Alcon stock sits 23.02 percent below its 52-week high

Published on 10/05/2026 at 11:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon's Q2 revenue reached USD 2.82 billion, up 6.42 percent sequentially. Alcon stock costs EUR 56.83 on October 5, 2026 after EUR 56.57.

Flat lay product photography on white marble. Contact lens case, lens solution bottle, soaking dish, and optometry trial lens kit arranged neatly with soft studio overhead lighting, clinical cleanliness, no text on items — Alcon CH0432492467: Flatlay mit Kontaktlinsenbehälter, Pflegelösung und Probierlinsen Set auf weißem Marmor, Illustration mit AI erstellt.

Alcon Inc. (ISIN CH0432492467) announced on September 29, 2026 that it would present new eye-care research at Academy 2026, while Alcon stock sits 23.02 percent below its SIX 52-week high of CHF 68.34. The company is using research in dry eye disease, contact lenses and contact lens care to support its product pipeline.

Academy research broadens the pipeline

According to Alcon on September 29, 2026, the company planned presentations covering patient satisfaction, symptoms and quality of life across its pharmaceutical and over-the-counter dry-eye portfolio. The program also included research on weekly replacement and daily disposable contact lenses, plus demonstrations of Voyager DSLT and Valeda PBM.

The commercial link is visible in the product lineup. Yahoo Finance reported on September 28, 2026 that Alcon launched Systane PRO Preservative-Free in Canada, with a stated relief duration of up to 12 hours.

Second-quarter revenue sets the base

For the quarter ended June 30, 2026, revenue was USD 2.82 billion, up 6.42 percent from USD 2.65 billion in the quarter ended March 31, 2026, according to Earnings Today. Adjusted earnings per share reached USD 0.84, versus a USD 0.77 consensus estimate, a 9.09 percent positive surprise.

The comparison shows why execution matters more than the event calendar alone. Alcon enters the next reporting cycle with product launches across Surgical and Vision Care, while the latest quarterly figures show revenue growth alongside a sharply lower reported operating result of USD 11.00 million in the second quarter.

Next results date is November 10

Zacks lists November 10, 2026 as Alcon's confirmed next earnings release date and gives a consensus estimate of USD 0.89 for earnings per share for the quarter ending September 2026. That estimate makes the next report a measurable test of whether new products can sustain the growth rate shown in the second quarter.

Alcon stock remains below its high

On SIX, Alcon's share price was CHF 52.60 on October 5, 2026, compared with a 52-week high of CHF 68.34. At Lang & Schwarz, the stock was trading at EUR 56.83 on October 5, 2026 at 11:38 a.m. CEST, plus 0.46 percent versus the prior close of EUR 56.57 on October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of Alcon stock.